<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02956850</url>
  </required_header>
  <id_info>
    <org_study_id>NP39305</org_study_id>
    <secondary_id>2016-003723-38</secondary_id>
    <nct_id>NCT02956850</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531</brief_title>
  <official_title>A Phase I, Sponsor-Open, Investigator-Blinded, Subject-Blinded, Multi-Center, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Administration of RO7020531: (1). Single and Multiple Ascending Doses in Healthy Male and Female Subjects; (2). 6-Week Treatment of Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This sponsor-open, investigator- and participant-blinded, multi-center study will assess the
      safety, tolerability, pharmacokinetics and pharmacodynamics of RO7020531 in healthy
      participants and in participants with chronic hepatitis B. Part I will be conducted in two
      portions: Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) which will include
      only healthy volunteers. Part II will commence after completion of the MAD portion of Part I
      and will include only Chronic Hepatitis B (CHB) participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2016</start_date>
  <completion_date type="Anticipated">April 19, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 19, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part I: Percentage of Participants With Adverse Events</measure>
    <time_frame>From randomization up to Day 41</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part II: Percentage of Participants With Adverse Events</measure>
    <time_frame>From randomization up to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part I: Maximum Observed Plasma Concentration (Cmax) of RO7020531; and its Metabolites Including RO7011785, RO7018822 and RO7033805</measure>
    <time_frame>SAD:Predose(0-2 hours [hrs] before dose),0.25,0.5,1,1.5,2,3,4,6,8,12,18,24,36,48 hrs postdose. MAD:Predose(0-2 hrs before dose),0.25,0.5,1,1.5,2,3,4,6,8,12,18,24 hrs postdose on Day 1,13; Predose(0-2 hrs before dose),2,6,24 hrs postdose on Day 3,5,7,9,11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Cmax of RO7020531; and its Metabolites Including RO7011785, RO7018822 and RO7033805</measure>
    <time_frame>Predose (0-2 hrs before dose), 0.25, 1, 2, 4, 6, 8, 24 hrs postdose on Days 1, 41; Predose (0-2 hrs before dose), 2-4 hrs postdose on Days 3, 7, 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Time to Reach Cmax (Tmax) of RO7020531; and its Metabolites Including RO7011785, RO7018822 and RO7033805</measure>
    <time_frame>SAD: Predose(0-2 hrs before dose),0.25,0.5,1,1.5,2,3,4,6,8,12,18,24,36,48 hrs postdose. MAD: Predose (0-2 hrs before dose), 0.25,0.5,1,1.5,2,3,4,6,8,12,18,24 hrs postdose on Days 1,13; Predose (0-2 hrs before dose), 2,6,24 hrs postdose on Days 3,5,7,9,11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Tmax of RO7020531; and its Metabolites Including RO7011785, RO7018822 and RO7033805</measure>
    <time_frame>Predose (0-2 hrs before dose), 0.25, 1, 2, 4, 6, 8, 24 hrs postdose on Days 1, 41; Predose (0-2 hrs before dose), 2-4 hrs postdose on Days 3, 7, 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUCinf) of RO7020531; and its Metabolites Including RO7011785, RO7018822 and RO7033805</measure>
    <time_frame>SAD: Predose(0-2 hrs before dose),0.25,0.5,1,1.5,2,3,4,6,8,12,18,24,36,48 hrs postdose. MAD: Predose (0-2 hrs before dose), 0.25,0.5,1,1.5,2,3,4,6,8,12,18,24 hrs postdose on Days 1,13; Predose (0-2 hrs before dose), 2,6,24 hrs postdose on Days 3,5,7,9,11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: AUCinf of RO7020531; and its Metabolites Including RO7011785, RO7018822 and RO7033805</measure>
    <time_frame>Predose (0-2 hrs before dose), 0.25, 1, 2, 4, 6, 8, 24 hrs postdose on Days 1, 41; Predose (0-2 hrs before dose), 2-4 hrs postdose on Days 3, 7, 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Area Under the Plasma Concentration Versus Time Curve up to the Last Measurable Concentration (AUClast) of RO7020531; and its Metabolites Including RO7011785, RO7018822 and RO7033805</measure>
    <time_frame>SAD: Predose(0-2 hrs before dose),0.25,0.5,1,1.5,2,3,4,6,8,12,18,24,36,48 hrs postdose. MAD: Predose (0-2 hrs before dose), 0.25,0.5,1,1.5,2,3,4,6,8,12,18,24 hrs postdose on Days 1,13; Predose (0-2 hrs before dose), 2,6,24 hrs postdose on Days 3,5,7,9,11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: AUClast of RO7020531; and its Metabolites Including RO7011785, RO7018822 and RO7033805</measure>
    <time_frame>Predose (0-2 hrs before dose), 0.25, 1, 2, 4, 6, 8, 24 hrs postdose on Days 1, 41; Predose (0-2 hrs before dose), 2-4 hrs postdose on Days 3, 7, 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Half-Life (t1/2) of RO7020531; and its Metabolites Including RO7011785, RO7018822 and RO7033805</measure>
    <time_frame>SAD: Predose(0-2 hrs before dose),0.25,0.5,1,1.5,2,3,4,6,8,12,18,24,36,48 hrs postdose. MAD: Predose (0-2 hrs before dose), 0.25,0.5,1,1.5,2,3,4,6,8,12,18,24 hrs postdose on Days 1,13; Predose (0-2 hrs before dose), 2,6,24 hrs postdose on Days 3,5,7,9,11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: t1/2 of RO7020531; and its Metabolites including RO7011785, RO7018822 and RO7033805</measure>
    <time_frame>Predose (0-2 hrs before dose), 0.25, 1, 2, 4, 6, 8, 24 hrs postdose on Days 1, 41; Predose (0-2 hrs before dose), 2-4 hrs postdose on Days 3, 7, 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Total Amount of RO7020531, RO7011785, RO7018822 and RO7033805 in Urine</measure>
    <time_frame>0 to 24 hrs post-dose on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I and II: Pharmacodynamics: Plasma Neopterin Levels</measure>
    <time_frame>SAD: Days 1, 2, 3, 5, 8. MAD: Days 1, 3, 5, 7, 13, 20. Part II: Days 1, 3, 7, 21, 41 (detailed timeframe is provided in outcome measure description)</time_frame>
    <description>SAD: Predose (0-2 hrs before dose), 2, 6, 12, 24, 48, 96 hrs postdose; Day 8. MAD: Predose (0-2 hrs before dose), 2, 6, 12, 24 hrs postdose on Day 1; Predose (0-2 hrs before dose), 2, 6, 24 hrs postdose on Days 3, 5, 7, 13; Day 20. Part II: Predose (0-2 hrs before dose), 6, 8, 24 hrs postdose on Day 1; Predose (0-2 hrs before dose), 4-6, 24 hrs postdose on Days 3, 7, 21; Predose (0-2 hrs before dose), 6, 24 hrs postdose on Day 41</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I and II: Pharmacodynamics: Plasma Interferon (INF)-alpha Levels</measure>
    <time_frame>SAD: Days 1, 8. MAD: Days 1, 3, 5, 7, 13, 20. Part II: Days 1, 3, 7, 21, 41 (detailed timeframe is provided in outcome measure description)</time_frame>
    <description>SAD: Predose (0-2 hrs before dose), 2, 6, 12, 24, 48, 96 hrs postdose; Day 8. MAD: Predose (0-2 hrs before dose), 2, 6, 12, 24 hrs postdose on Day 1; Predose (0-2 hrs before dose), 2, 6, 24 hrs postdose on Days 3, 5, 7, 13; Day 20. Part II: Predose (0-2 hrs before dose), 6, 8, 24 hrs postdose on Day 1; Predose (0-2 hrs before dose), 4-6, 24 hrs postdose on Days 3, 7, 21; Predose (0-2 hrs before dose), 6, 24 hrs postdose on Day 41</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I and II: Pharmacodynamics: Plasma Interferon Gamma-Inducible Protein 10 (IP-10) Levels</measure>
    <time_frame>SAD: Days 1, 8. MAD: Days 1, 3, 5, 7, 13, 20. Part II: Days 1, 3, 7, 21, 41 (detailed timeframe is provided in outcome measure description)</time_frame>
    <description>SAD: Predose (0-2 hrs before dose), 2, 6, 12, 24, 48, 96 hrs postdose; Day 8. MAD: Predose (0-2 hrs before dose), 2, 6, 12, 24 hrs postdose on Day 1; Predose (0-2 hrs before dose), 2, 6, 24 hrs postdose on Days 3, 5, 7, 13; Day 20. Part II: Predose (0-2 hrs before dose), 6, 8, 24 hrs postdose on Day 1; Predose (0-2 hrs before dose), 4-6, 24 hrs postdose on Days 3, 7, 21; Predose (0-2 hrs before dose), 6, 24 hrs postdose on Day 41</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I and II: Pharmacodynamics: Plasma Tumor Necrosis Factor (TNF)-alpha Levels</measure>
    <time_frame>SAD: Days 1, 8. MAD: Days 1, 3, 5, 7, 13, 20. Part II: Days 1, 3, 7, 21, 41 (detailed timeframe is provided in outcome measure description)</time_frame>
    <description>SAD: Predose (0-2 hrs before dose), 2, 6, 12, 24, 48, 96 hrs postdose; Day 8. MAD: Predose (0-2 hrs before dose), 2, 6, 12, 24 hrs postdose on Day 1; Predose (0-2 hrs before dose), 2, 6, 24 hrs postdose on Days 3, 5, 7, 13; Day 20. Part II: Predose (0-2 hrs before dose), 6, 8, 24 hrs postdose on Day 1; Predose (0-2 hrs before dose), 4-6, 24 hrs postdose on Days 3, 7, 21; Predose (0-2 hrs before dose), 6, 24 hrs postdose on Day 41</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I and II: Pharmacodynamics: Plasma IL-6 Levels</measure>
    <time_frame>SAD: Days 1, 8. MAD: Days 1, 3, 5, 7, 13, 20. Part II: Days 1, 3, 7, 21, 41 (detailed timeframe is provided in outcome measure description)</time_frame>
    <description>SAD: Predose (0-2 hrs before dose), 2, 6, 12, 24, 48, 96 hrs postdose; Day 8. MAD: Predose (0-2 hrs before dose), 2, 6, 12, 24 hrs postdose on Day 1; Predose (0-2 hrs before dose), 2, 6, 24 hrs postdose on Days 3, 5, 7, 13; Day 20. Part II: Predose (0-2 hrs before dose), 6, 8, 24 hrs postdose on Day 1; Predose (0-2 hrs before dose), 4-6, 24 hrs postdose on Days 3, 7, 21; Predose (0-2 hrs before dose), 6, 24 hrs postdose on Day 41</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I and II: Pharmacodynamics: Plasma IL-10 Levels</measure>
    <time_frame>SAD: Days 1, 8. MAD: Days 1, 3, 5, 7, 13, 20. Part II: Days 1, 3, 7, 21, 41 (detailed timeframe is provided in outcome measure description)</time_frame>
    <description>SAD: Predose (0-2 hrs before dose), 2, 6, 12, 24, 48, 96 hrs postdose; Day 8. MAD: Predose (0-2 hrs before dose), 2, 6, 12, 24 hrs postdose on Day 1; Predose (0-2 hrs before dose), 2, 6, 24 hrs postdose on Days 3, 5, 7, 13; Day 20. Part II: Predose (0-2 hrs before dose), 6, 8, 24 hrs postdose on Day 1; Predose (0-2 hrs before dose), 4-6, 24 hrs postdose on Days 3, 7, 21; Predose (0-2 hrs before dose), 6, 24 hrs postdose on Day 41</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I and II: Pharmacodynamics: Plasma IL-12p40 Levels</measure>
    <time_frame>SAD: Days 1, 8. MAD: Days 1, 3, 5, 7, 13, 20. Part II: Days 1, 3, 7, 21, 41 (detailed timeframe is provided in outcome measure description)</time_frame>
    <description>SAD: Predose (0-2 hrs before dose), 2, 6, 12, 24, 48, 96 hrs postdose; Day 8. MAD: Predose (0-2 hrs before dose), 2, 6, 12, 24 hrs postdose on Day 1; Predose (0-2 hrs before dose), 2, 6, 24 hrs postdose on Days 3, 5, 7, 13; Day 20. Part II: Predose (0-2 hrs before dose), 6, 8, 24 hrs postdose on Day 1; Predose (0-2 hrs before dose), 4-6, 24 hrs postdose on Days 3, 7, 21; Predose (0-2 hrs before dose), 6, 24 hrs postdose on Day 41</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I and II: Pharmacodynamics: Plasma Interferon-Stimulated Gene (ISG) 15 messenger Ribonucleic Acid (mRNA) Levels</measure>
    <time_frame>SAD: Days 1, 8. MAD: Days 1, 3, 5, 7, 13, 20. Part II: Days 1, 3, 7, 21, 41 (detailed timeframe is provided in outcome measure description)</time_frame>
    <description>SAD: Predose (0-2 hrs before dose), 2, 6, 12, 24, 48, 96 hrs postdose; Day 8. MAD: Predose (0-2 hrs before dose), 2, 6, 12, 24 hrs postdose on Day 1; Predose (0-2 hrs before dose), 2, 6, 24 hrs postdose on Days 3, 5, 7, 13; Day 20. Part II: Predose (0-2 hrs before dose), 6, 8, 24 hrs postdose on Day 1; Predose (0-2 hrs before dose), 4-6, 24 hrs postdose on Days 3, 7, 21; Predose (0-2 hrs before dose), 6, 24 hrs postdose on Day 41</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I and II: Pharmacodynamics: Plasma Oligoadenylate Synthetase (OAS)-1 mRNA Levels</measure>
    <time_frame>SAD: Days 1, 8. MAD: Days 1, 3, 5, 7, 13, 20. Part II: Days 1, 3, 7, 21, 41 (detailed timeframe is provided in outcome measure description)</time_frame>
    <description>SAD: Predose (0-2 hrs before dose), 2, 6, 12, 24, 48, 96 hrs postdose; Day 8. MAD: Predose (0-2 hrs before dose), 2, 6, 12, 24 hrs postdose on Day 1; Predose (0-2 hrs before dose), 2, 6, 24 hrs postdose on Days 3, 5, 7, 13; Day 20. Part II: Predose (0-2 hrs before dose), 6, 8, 24 hrs postdose on Day 1; Predose (0-2 hrs before dose), 4-6, 24 hrs postdose on Days 3, 7, 21; Predose (0-2 hrs before dose), 6, 24 hrs postdose on Day 41</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I and II: Pharmacodynamics: Plasma Myxovirus Resistance 1 gene (MX1) mRNA Levels</measure>
    <time_frame>SAD: Days 1, 8. MAD: Days 1, 3, 5, 7, 13, 20. Part II: Days 1, 3, 7, 21, 41 (detailed timeframe is provided in outcome measure description)</time_frame>
    <description>SAD: Predose (0-2 hrs before dose), 2, 6, 12, 24, 48, 96 hrs postdose; Day 8. MAD: Predose (0-2 hrs before dose), 2, 6, 12, 24 hrs postdose on Day 1; Predose (0-2 hrs before dose), 2, 6, 24 hrs postdose on Days 3, 5, 7, 13; Day 20. Part II: Predose (0-2 hrs before dose), 6, 8, 24 hrs postdose on Day 1; Predose (0-2 hrs before dose), 4-6, 24 hrs postdose on Days 3, 7, 21; Predose (0-2 hrs before dose), 6, 24 hrs postdose on Day 41</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I and II: Pharmacodynamics: Plasma Toll-Like Receptor (TLR) 7 mRNA Levels</measure>
    <time_frame>SAD: Days 1, 8. MAD: Days 1, 3, 5, 7, 13, 20. Part II: Days 1, 3, 7, 21, 41 (detailed timeframe is provided in outcome measure description)</time_frame>
    <description>SAD: Predose (0-2 hrs before dose), 2, 6, 12, 24, 48, 96 hrs postdose; Day 8. MAD: Predose (0-2 hrs before dose), 2, 6, 12, 24 hrs postdose on Day 1; Predose (0-2 hrs before dose), 2, 6, 24 hrs postdose on Days 3, 5, 7, 13; Day 20. Part II: Predose (0-2 hrs before dose), 6, 8, 24 hrs postdose on Day 1; Predose (0-2 hrs before dose), 4-6, 24 hrs postdose on Days 3, 7, 21; Predose (0-2 hrs before dose), 6, 24 hrs postdose on Day 41</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Percentage of T-Cells</measure>
    <time_frame>Predose (0-2 hrs before dose) on Day 21; 24 hrs postdose on Day 41; Week 9 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Percentage of B-Cells</measure>
    <time_frame>Predose (0-2 hrs before dose) on Day 21; 24 hrs postdose on Day 41; Week 9 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Percentage of NK Cells</measure>
    <time_frame>Predose (0-2 hrs before dose) on Day 21; 24 hrs postdose on Day 41; Week 9 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Percentage of Myeloid Cells</measure>
    <time_frame>Predose (0-2 hrs before dose) on Day 21; 24 hrs postdose on Day 41; Week 9 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Percentage of Plasmacytoid Dendritic Cells (pDCs)</measure>
    <time_frame>Predose (0-2 hrs before dose) on Day 21; 24 hrs postdose on Day 41; Week 9 and Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Part I: SAD in Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will receive single dose of RO7020531 or matching placebo orally on Day 1 of each cohort. A planned dose-escalation sequence for SAD is 3 milligrams (mg), 10 mg, 20 mg, 40 mg, 60 mg, 100 mg, 140 mg, and 170 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I: MAD in Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will receive RO7020531 (dose as selected based on safety, PK and PD data of SAD cohorts) or matching placebo orally every other day (QOD) from Day 1 through to Day 13.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II: CHB Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHB participants will receive RO7020531 (dose as selected based on safety, PK and PD data of MAD cohorts) or matching placebo orally QOD from Day 1 through to Day 41.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching to RO7020531 will be administered as per schedule specified in the respective arm.</description>
    <arm_group_label>Part I: SAD in Healthy Volunteers</arm_group_label>
    <arm_group_label>Part I: MAD in Healthy Volunteers</arm_group_label>
    <arm_group_label>Part II: CHB Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7020531</intervention_name>
    <description>RO7020531 will be administered as per schedule specified in the respective arm.</description>
    <arm_group_label>Part I: SAD in Healthy Volunteers</arm_group_label>
    <arm_group_label>Part I: MAD in Healthy Volunteers</arm_group_label>
    <arm_group_label>Part II: CHB Participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Part 1: SAD and MAD in Healthy Volunteers

          -  A Body Mass Index (BMI) between 18 to 32 kilograms per square meter (kg/m^2),
             inclusive

          -  Non-smokers, or use of less than (&lt;) 10 cigarettes (or equivalent nicotine-containing
             product) per day

          -  Negative Anti-Nuclear Antibody (ANA) test; or positive with dilutions not greater than
             1:40 and with no associated history or symptoms of potential connective tissue disease
             or other immune-mediated diseases

        Part 2: CHB Participants

          -  A BMI between 18 to 32 kg/m^2, inclusive

          -  CHB infection (positive test for Hepatitis B surface antigen [HBsAg] for more than 6
             months prior to randomization)

          -  HBsAg detectable at screening

          -  Hepatitis B Virus (HBV) deoxyribonucleic acid (DNA) &lt;90 international units per
             milliliter (IU/mL) for at least 6 months prior to randomization; HBV DNA &lt;90 IU/mL at
             screening by Roche Cobas assay

          -  Negative ANA test; or positive with dilutions not greater than 1:40 and with no
             associated history or symptoms of potential connective tissue disease or other
             immune-mediated diseases

          -  Liver biopsy, Fibroscan® or equivalent elastography test obtained within 6 months
             prior to randomization demonstrating liver disease consistent with chronic HBV
             infection with absence of cirrhosis and absence of extensive bridging fibrosis
             (cirrhosis or extensive bridging fibrosis are defined as greater than or equal to
             (&gt;/=) Metavir 3, recommended cut-off for Fibroscan 8.5 kilopascals [kPa])

          -  On treatment with tenofovir, entecavir, adefovir, or telbivudine, either as single
             agents or in combination, for at least 6 months

        Exclusion Criteria:

        Part 1: SAD and MAD in Healthy Volunteers

          -  History of immunologically mediated disease (e.g., inflammatory bowel disease,
             idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune haemolytic
             anemia, scleroderma, severe psoriasis, rheumatoid arthritis, multiple sclerosis, or
             any other autoimmune disease); clinically significant psychiatric disease, acute
             infection (e.g., influenza), gastrointestinal (GI) disease (including inflammatory
             bowel disease, peptic ulcer disease, GI hemorrhage)

          -  History of having received or currently receiving any systemic anti-neoplastic
             (including radiation) or immune-modulatory treatment (including systemic oral or
             inhaled corticosteroids, IFN or pegylated interferon [PEG-IFN]) within the 8 weeks
             prior to the first dose of study drug or the expectation that such treatment will be
             needed at any time during the study

          -  Any clinically significant concomitant disease or condition that could interfere with,
             or for which the treatment of might interfere with, the conduct of the study, or that
             would, in the opinion of the Investigator, pose an unacceptable risk to the
             participant in this study

          -  Positive Hepatitis A virus antibody (HAV Ab IgM), HBsAg, Hepatitis C antibody (HCV
             Ab), or positive for human immunodeficiency virus (HIV) at screening

          -  History of clinically significant thyroid disease; also, participants with clinically
             significant elevated thyroid-stimulating hormone (TSH) concentrations at screening

          -  Positive results for anti-mitochondrial antibody (AMA), anti-smooth muscle antibody
             (ASMA) or thyroid peroxidase antibody

        Part 2: CHB Participants

          -  History of liver cirrhosis

          -  History or other evidence of bleeding from esophageal varices

          -  Decompensated liver disease (e.g., Child-Pugh Class B or C clinical classification or
             clinical evidence such as ascites or varices)

          -  History or other evidence of a medical condition associated with chronic liver disease
             other than HBV infection (e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver
             disease, toxin exposure, thalassemia, nonalcoholic steato-hepatitis, etc.). A clinical
             diagnosis of fatty liver is allowed provided that non alcoholic steatohepatitis (NASH)
             has been excluded by liver biopsy or non-invasive markers

          -  Documented history or other evidence of metabolic liver disease within one year of
             randomization

          -  Positive test for Hepatitis A virus (IgM anti-HAV), HCV, Hepatitis D or HIV

          -  History of or suspicion of hepatocellular carcinoma or alpha fetoprotein &gt;/=13
             nanograms per milliliter (ng/mL) at screening

          -  History of immunologically mediated disease (e.g., inflammatory bowel disease,
             idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune haemolytic
             anemia, scleroderma, severe psoriasis, rheumatoid arthritis, multiple sclerosis, or
             any other autoimmune disease); clinically significant psychiatric disease, acute
             infection (e.g., influenza), GI disease (including inflammatory bowel disease, peptic
             ulcer disease, GI hemorrhage)

          -  History of having received or currently receiving any systemic anti-neoplastic
             (including radiation) or immune-modulatory treatment (including systemic oral or
             inhaled corticosteroids,IFN or PEG-IFN) within the 8 weeks prior to the first dose of
             study drug or the expectation that such treatment will be needed at any time during
             the study

          -  History of organ transplantation

          -  Clinically significant thyroid disease; also, participants with clinically significant
             elevated TSH concentrations at screening

          -  Positive results for AMA, ASMA or thyroid peroxidase antibody
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: NP39305 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gastroenterology department, Second clinic of internal diseases</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>COMAC Medical; Clinical Research Unit for Phase I</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Chinese University of Hong Kong</name>
      <address>
        <city>Shatin</city>
        <zip>123456</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Di Modena Policlinico; U.O. Farmacia</name>
      <address>
        <city>Modena</city>
        <state>Emilia-Romagna</state>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST PAPA GIOVANNI XXIII; Epatologia e gastroenterologia pediatrica e dei trapianti</name>
      <address>
        <city>Bergamo</city>
        <state>Lombardia</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medicina Generale ed Epatologia (Humanitas-Rozzano)</name>
      <address>
        <city>Rozzano</city>
        <state>Lombardia</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum Universiteit Amsterdam; Dermatology and VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1100 DD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies</name>
      <address>
        <city>Auckland</city>
        <zip>1142</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakorn Chiang Mai Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>King College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Korea, Republic of</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2016</study_first_submitted>
  <study_first_submitted_qc>November 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2016</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

